89BIO (ETNB)
(Delayed Data from NSDQ)
$8.29 USD
-0.02 (-0.24%)
Updated Sep 19, 2024 04:00 PM ET
After-Market: $8.28 -0.01 (-0.12%) 7:40 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Brokerage Reports
0 items in cart
89BIO [ETNB]
Reports for Purchase
Showing records 1 - 20 ( 30 total )
Company: 89BIO
Industry: Medical - Biomedical and Genetics
2Q Recap: With Two ENLIGHTEN Phase 3 MASH Studies Ongoing, Next Key Readout is ENTRUST SHTG Results in 2025; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: 89BIO
Industry: Medical - Biomedical and Genetics
Pegozafermin Week 48 Dataset Shows Extension of Effects Consistent With Those Observed at Week 24;
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: 89BIO
Industry: Medical - Biomedical and Genetics
KOL Event Highlights Pegozefermin''s Anti-Fibrotic and Metabolic Effects As Key Attributes in F4 MASH
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: 89BIO
Industry: Medical - Biomedical and Genetics
Phase 3 ENLIGHTEN-Cirrhosis Trial Begins; Month 24 Data Could Support F4 MASH Accelerated Approval
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: 89BIO
Industry: Medical - Biomedical and Genetics
1Q Recap: ENLIGHTEN-Cirrhosis Initiation On Target in 2Q24
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: 89BIO
Industry: Medical - Biomedical and Genetics
Pegozafermin Receives PRIME Status From EMA For MASH
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: 89BIO
Industry: Medical - Biomedical and Genetics
Phase 3 ENLIGHTEN-Fibrosis Trial Kicks Off; ENLIGHTENCirrhosis Initiation on Target in 2Q24; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: 89BIO
Industry: Medical - Biomedical and Genetics
4Q Recap; Pegozafermin ENLIGHTEN Phase 3 MASH Program to Begin Within Weeks
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: 89BIO
Industry: Medical - Biomedical and Genetics
Enter a New Key Challenger in the MASH Race: Sagimet''s Denifanstat Looks to Enter Phase 3 by YE24
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: 89BIO
Industry: Medical - Biomedical and Genetics
Phase 3 ENLIGHTEN Program of PGZ to Start in 1H24; Model Updates Following Equity Raise; PT to $32
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: 89BIO
Industry: Medical - Biomedical and Genetics
Pegozafermin''s Phase 3 NASH Program Aligned With the FDA and EMA; First of Two Studies to Begin in 1Q24; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: 89BIO
Industry: Medical - Biomedical and Genetics
Phase 2b ENLIVEN Week 48 Dataset Extends Week 24 Findings
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: 89BIO
Industry: Medical - Biomedical and Genetics
Optimized Entry and Exit Levels for ETNB 112123
Provider: Stock Traders Daily
Analyst: Research Department
Company: 89BIO
Industry: Medical - Biomedical and Genetics
3Q Recap; Final Pegozafermin Phase 3 Program Design Expected in 4Q23 to Enable 1H24 Initiation; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: 89BIO
Industry: Medical - Biomedical and Genetics
Pegozafermin Granted Breakthrough Therapy Designation; Planned Discussions to Finalize Phase 3 Design in 4Q; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: 89BIO
Industry: Medical - Biomedical and Genetics
2Q Recap: Regulatory Discussions on Phase 3 Path for NASH Planned for 2H23; Phase 3 ENTRUST Study Continues to Enroll
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: 89BIO
Industry: Medical - Biomedical and Genetics
Phase 3 ENTRUST Trial Initiated; SHTG Safety Data Could Be Part of NASH Registrational Package; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: 89BIO
Industry: Medical - Biomedical and Genetics
1Q Recap; Phase 3 SHTG Study Initiates in 2Q23; Adding NASH Cirrhosis to our Model; Increasing PT to $35; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: 89BIO
Industry: Medical - Biomedical and Genetics
ENLIVEN''ing the ETNB Shares With Broad, Unequivocally Robust and Definitive PoC Results in NASH; Raise PT to $30
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: 89BIO
Industry: Medical - Biomedical and Genetics
Our Take: Imminent NASH Catalyst to ENLIVEN the Shares For One of Our Top Picks; Affirm Buy, Moderate PT to $25
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E